SpayVac® EPA registration is in progress and available for experimental use only.
SpayVac Publications can be found on our About SpayVac page beneath the FAQs
Immunovaccine license agreement for exclusive use of DPX® and VacciMax for use in developing contraceptive vaccines for feral, invasive, and overabundant mammal populations. April 23, 2018. Madison, WI, USA; Victoria, BC, Canada; and Halifax, NS Canada
SpayVac-for-Wildlife, Inc., announces an agreement with Immunovaccine, Inc. (TSX:IMV) (OTC:IMMVF) who granted them a license to two proprietary vaccine delivery platforms, VacciMax® and DepoVax™. SpayVac-for-Wildlife, Inc. (SFW Inc.) will use these platforms to develop immunocontraceptive vaccines for use in populations of overabundant, feral and invasive mammals. SFW Inc.’s mission is to commercialize humane birth control tools for these over abundant populations.
SFW Inc. will produce and market SpayVac®, a pZP vaccine, using both of IMV’s proprietary VacciMax and DepoVax platforms. SFW Inc. will have global exclusive rights to use both of these platforms to develop humane, immunocontraceptive vaccines for control of overabundant, feral and invasive wildlife populations.
We are accumulating a collection of links to other immuoncontraceptive-centric organizations